What is IPH4502?
IPH4502 is a novel topoisomerase I inhibitor Antibody Drug Conjugate (ADC) conjugated to exatecan targeting Nectin-4.
Nectin-4 is a cell membrane adhesion protein overexpressed in several solid tumors, including urothelial, breast, esophageal, lung, ovarian, and pancreatic cancers, with limited expression in normal tissues.
In non-clinical models, IPH45 was well tolerated and shows anti-tumor efficacy in vitro and in vivo.
Mechanism of action
| IPH4502 Nectin-4 Proprietary program | Phase 1 clinical trial, in patients with advanced solid tumors known to express Nectin-4.
| |||
| Preclinical | Phase 1 | Phase 2 | Phase 3 | |